Search
SOLACI Congress
HomeStructural heart diseaseValvular Aortic valve

Valvular Aortic valve

View Category

Other

Diastolic Dysfunction Should Be Considered in TAVR

Aortic stenosis increases afterload creating hypertrophy as a compensation mechanism to maintain minute volume. This leads to...
solaci -
Learn More
Structural heart disease

Delayed Coronary Obstruction After TAVR: A Complication We Had Not Considered

Delayed coronary obstruction (after TAVR, outside the cath lab) is a rare complication with high mortality rates,...
solaci -
Learn More
Structural heart disease

Which Low-Flow, Low-Gradient Patients Benefit from Valve Replacement?

A mean gradient ≥40 mmHg, an aortic valve area ≤1 cm², or a combination of both, during dobutamine stress...
solaci -
Learn More
Structural heart disease

Reverse Myocardial Remodeling Following Valve Replacement

After aortic valve replacement, focal fibrosis does not resolve, but diffuse fibrosis and cell hypertrophy regress. As...
solaci -
Learn More
Structural heart disease

NOTION: 5-Year Outcomes of TAVR vs. Surgery in Low-Risk Patients are Promising

At 5 years, there were no differences in all-cause death, stroke, acute myocardial infarction, or all of these...
solaci -
Learn More
Structural heart disease

Permanent Pacemaker: still TAVR’s Aquila’s Heel

TAVR has shown benefits in high risk patients (prohibitive) and in intermediate risk patients, but the need for permanent...
solaci -
Learn More
Structural heart disease

Next-Day Discharge after TAVR: Is It Viable?

Next-day discharge after transfemoral transcatheter aortic valve replacement (TAVR) might be viable, with no major complications at 30 days...
solaci -
Learn More
Structural heart disease

Red Light for TAVR in Low Surgical Risk Patients

A new study raises an alarm against expanding transcatheter aortic valve replacement (TAVR) procedures to low surgical risk...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

AHA 2024 | VANISH2 Trial

Dr. Omar Tupayachi - 0
Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

Dr. Omar Tupayachi - 0
It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Dr. Omar Tupayachi - 0
Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Institutional News

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy